A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.

作者
Nehal J. Lakhani,Alexander I. Spira,Anthony W. Tolcher,Trupti Lingaraj,Marissa Timothy,Wilmin P. Bartolini,Nerymar Ortiz-Otero,Katherine A. Kacena,Sergio Santillana
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): TPS3185-TPS3185
标识
DOI:10.1200/jco.2024.42.16_suppl.tps3185
摘要

TPS3185 Background: Alterations in the RAS/RAF/MEK/ERK pathway are the most common drivers of oncogenesis. MEK is a clinically validated cancer target and despite FDA approval of several MEK inhibitors, their clinical utility has been limited to BRAF V600 mutant cancers and NF1 mutant neurofibromas mostly due to early emergence of resistance and low therapeutic indices. IK-595, a potent novel MEK-RAF molecular glue, is being developed to overcome these limitations. IK-595 traps MEK in an inactive complex with all RAF isoforms and blocks RAF-dependent MEK phosphorylation, thereby alleviating CRAF-mediated MEK reactivation that hinders the efficacy of approved MEK inhibitors in RAS/RAF-driven tumors, in addition to kinase independent CRAF activity. IK-595 exhibits potent single agent activity in a wide range of in vivo cancer models harboring various RAS/RAF alterations, including, but not limited to, lung, pancreatic, colorectal cancer (CRC), melanoma, and AML. The preclinical pharmacokinetic profile of IK-595 also enables flexible dosing schedules resulting in a broader therapeutic window. Methods: This is a phase 1, first-in-human, open-label, multicenter study to evaluate IK-595 as monotherapy in patients with RAS- or RAF-altered advanced solid tumors for whom there are no other further treatment options known to confer clinical benefit. Dose escalation uses a Bayesian Optimal Interval Design (BOIN) in patients with advanced and unresectable, or metastatic solid tumors with confirmed RAS/RAF gene alterations. Backfilling of cleared dose levels with key target indications will initiate upon achievement of efficacious plasma exposures. Dose expansion will occur in genetically defined cohorts, for example NRAS-mutant CRC and malignant melanoma, as well as BRAF non-V600 and KRAS mutant tumors using a Simon 2-stage adaptive design. IK-595 will initially be administered on an intermittent dosing schedule in 30-day cycles. Additional dosing schedules may be explored. Primary objectives of the study are to evaluate safety and tolerability of IK-595 and to determine the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD). Secondary objectives include evaluation of preliminary antitumor activity by RECIST 1.1, pharmacokinetic (PK) parameters, and pharmacodynamic effects of IK-595 on pERK in paired tumor biopsies. Key exploratory endpoints include changes in pERK in peripheral blood cells, changes in pERK target genes in tumor biopsies, and assessment of candidate baseline response biomarkers. The study began in December 2023 and enrollment in Cohort 1 was completed with no DLTs; dose escalation continues to enroll. Clinical trial information: NCT.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型的应助被科研通管家采纳,获得10
刚刚
脑洞疼的应助被科研通管家采纳,获得10
1秒前
顺顺当当发布了新的文献求助10
1秒前
Orange的应助被科研通管家采纳,获得10
1秒前
JamesPei的应助被科研通管家采纳,获得10
1秒前
cdercder的应助被科研通管家采纳,获得10
1秒前
1秒前
FashionBoy的应助被科研通管家采纳,获得10
1秒前
美好觅松的应助被科研通管家采纳,获得20
1秒前
传奇3的应助被科研通管家采纳,获得10
1秒前
清河响啊啊完成签到,获得积分20
1秒前
可爱的函函的应助被QQ采纳,获得10
1秒前
2秒前
bkagyin的应助被科研通管家采纳,获得20
2秒前
华仔的应助被科研通管家采纳,获得30
2秒前
852的应助被科研通管家采纳,获得10
2秒前
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
2秒前
隐形曼青的应助被科研通管家采纳,获得20
2秒前
领导范儿的应助被dianhuaxue采纳,获得10
3秒前
4秒前
4秒前
holoka发布了新的文献求助10
5秒前
6秒前
元舒甜完成签到,获得积分10
6秒前
李瑞程发布了新的文献求助10
7秒前
7秒前
Akim的应助被芜湖湖采纳,获得10
7秒前
威威完成签到,获得积分10
7秒前
8秒前
8秒前
万能图书馆的应助被袋袋采纳,获得10
9秒前
Paranoieam发布了新的文献求助10
9秒前
Lisa的应助被叫滚滚采纳,获得10
10秒前
minminmin完成签到,获得积分10
11秒前
11秒前
serein发布了新的文献求助10
11秒前
幽默兰完成签到,获得积分10
12秒前
PL发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239